One of the critical areas of focus has been the role of synaptic function in the development of both ASD and comorbid mental health disorders. Variations in genes involved in synaptic function, such as the SHANK3 gene, have been consistently implicated in the development of autism. Evidence from de novo mutation studies and CNV analyses classifies SHANK3 as a high-confidence risk gene for ASD ([32]). Its link to comorbid anxiety symptoms is understood through its role in cortico-striatal circuits that underlie fear and compulsive behaviors, although this connection is less frequently confirmed by large-scale GWAS specifically for anxiety disorders ([39]). A comprehensive gene list update confirms SHANK3 as one of the high-confidence risk genes for ASD and associated neurodevelopmental disorders ([32]). These findings underscore the importance of synaptic dysfunction as a common underlying mechanism contributing to both ASD and anxiety, highlighting the potential for targeted therapeutic interventions that address synaptic integrity.

Similarly, the SLC6A4 gene, which encodes the serotonin transporter, has been extensively studied in mood disorders. While polymorphisms in SLC6A4 are well-established risk factors for depression in the general population via GWAS ([44]), their specific contribution to depression in ASD is supported by candidate gene studies but remains an area of active investigation ([58]). This insight opens avenues for exploring serotonergic drugs as potential treatments for comorbid depression in ASD, although the unique neurobiology of autism necessitates careful consideration of drug efficacy and safety.

In addition to specific gene mutations, the study of rare copy number variations (CNVs) and de novo mutations has provided further evidence for the shared genetic architecture between ASD and ADHD. For example, CNVs at the 16p11.2 locus are strongly associated with ASD, while their association with ADHD is less direct but supported by the presence of ADHD symptoms in individuals with these CNVs, suggesting a pleiotropic effect ([47]). Similarly, CNVs at 22q11.2 are linked to increased risk for both ASD and ADHD, although the phenotypic expression varies, indicating complex gene-brain-behavior pathways ([62]). These regions contain multiple genes involved in brain development, synaptic function, and neural connectivity, further supporting the notion that disruptions in these pathways may underlie the shared etiology of ASD and its comorbid mental health disorders ([21]).

Large-scale genome-wide association studies (GWAS) have further elucidated the shared genetic architecture between ASD and ADHD. Cross-disorder GWAS have identified common genetic variants, such as those at the 2p16.3 locus, that show significant association with both ASD and ADHD, contributing to the polygenic risk for these conditions ([12]; [15]). These findings underscore the polygenic nature of the comorbidity and highlight the role of common variants in addition to rare CNVs. These findings suggest that the cumulative effect of multiple genetic variants may contribute to the shared etiology of ASD and its comorbid mental health disorders, providing a more comprehensive understanding of the genetic underpinnings of these complex conditions.

Furthermore, WGS has enabled the identification of rare de novo mutations that contribute to the risk of both ASD and related psychiatric disorders. De novo mutations, which are genetic changes that occur spontaneously and are not inherited from either parent, have been found to play a significant role in the development of ASD. Recent studies have identified de novo mutations in genes such as CHD8, SCN2A, and SYNGAP1, which are involved in chromatin remodeling, ion channel function, and synaptic signaling, respectively ([27]; [56]). These genes are critical for normal brain development and function, and their disruption may lead to the neurodevelopmental abnormalities observed in ASD and its comorbidities. The identification of these mutations not only enhances our understanding of the genetic basis of ASD but also provides potential targets for the development of novel therapeutic strategies.

Epigenetic research has significantly advanced our understanding of how gene expression is modulated by environmental influences, particularly in the context of Autism Spectrum Disorder (ASD) and its comorbid mental health conditions. Recent studies have demonstrated that epigenetic modifications can significantly impact the expression of genes implicated in ASD and its associated mental health disorders, such as anxiety, depression, and ADHD. For instance, DNA methylation, which involves adding a methyl group to the DNA molecule, can regulate gene expression by silencing or activating specific genes ([16]). Alterations in DNA methylation patterns have been observed in several key genes involved in synaptic function, immune response, and neurodevelopment in individuals with ASD, suggesting that these epigenetic changes may play a crucial role in the development of comorbid conditions.

One study by [33] identified distinct DNA methylation patterns in genes associated with synaptic transmission and neuroplasticity, such as the BDNF (brain-derived neurotrophic factor) gene, in individuals with ASD. While these cross-sectional studies in humans suggest a correlation between epigenetic markers and comorbid symptoms, they cannot establish causation. The precise role of these changes in the development of comorbid conditions remains to be definitively proven ([33]; [46]). Similarly, [46] found that histone modifications, which involve chemical changes to the proteins around which DNA is wound, could influence the expression of genes related to immune function and inflammation in ASD. These findings suggest that epigenetic mechanisms may contribute to the immune dysregulation often observed in individuals with autism, which in turn may exacerbate the risk of developing anxiety and depression.

Moreover, the role of non-coding RNAs, such as microRNAs (miRNAs), in regulating gene expression has gained increasing attention in recent years. MiRNAs are small RNA molecules that can modulate gene expression post-transcriptionally by binding to target messenger RNAs (mRNAs) and preventing their translation into proteins. Research has shown that specific miRNAs are dysregulated in individuals with ASD, potentially contributing to the development of comorbid mental health disorders. For example, a study by [40] identified altered miRNA expression profiles in the prefrontal cortex of individuals with ASD, with several miRNAs implicated in regulating genes involved in synaptic function and neuronal connectivity. These dysregulated miRNAs may contribute to the neural circuitry abnormalities observed in autism, leading to increased vulnerability to anxiety, depression, and other comorbidities.

The interaction between genetic predispositions and environmental factors, often referred to as gene-environment interactions, is a critical determinant of neurodevelopmental outcomes in individuals with ASD. These interactions can influence the severity and expression of ASD symptoms, as well as the likelihood of developing comorbid mental health disorders. For instance, individuals with specific genetic vulnerabilities, such as mutations in the SLC6A4 gene, may be more susceptible to the effects of environmental stressors, leading to an increased risk of developing depression ([8]). This gene encodes the serotonin transporter, which is crucial for regulating serotonin levels in the brain, a neurotransmitter that plays a key role in mood regulation.

Recent research has highlighted the importance of considering both genetic and environmental factors in understanding the etiology of ASD and its comorbidities. For example, a study by [28] found that children with ASD who were exposed to higher levels of prenatal maternal stress exhibited more severe anxiety and depressive symptoms, particularly if they carried specific genetic variants associated with stress sensitivity. These findings suggest that interventions targeting both genetic predispositions and environmental risk factors may be more effective in managing comorbid conditions in individuals with ASD.

Moreover, the concept of “epigenetic plasticity” has emerged as a promising area of research, highlighting the potential for reversing or modifying epigenetic changes through environmental interventions. For example, animal studies have shown that enriching the environment with sensory, social, and cognitive stimuli can lead to positive epigenetic modifications in genes involved in synaptic plasticity and stress response ([43]). However, a key limitation in translating these findings to clinical practice is that most evidence for the direct modification of epigenetic marks by environmental interventions comes from animal models. Direct evidence that such interventions can reverse adverse epigenetic changes and subsequently reduce psychiatric comorbidity in humans with ASD is currently lacking and requires longitudinal studies.

The amygdala, prefrontal cortex, and hippocampus are among the most studied brain regions in ASD research due to their roles in emotion regulation, executive function, and memory. Neuroimaging studies have consistently shown that alterations in these regions are common in individuals with both autism and anxiety or depression ([25]; [45]). For instance, the amygdala, which is central to processing fear and emotional responses, often exhibits hyperactivity in individuals with ASD, particularly those with comorbid anxiety. This finding is robustly supported by ASD-specific neuroimaging studies that have correlated amygdala hyperarousal with heightened fear responses and social withdrawal in this population ([25]). This hyperactivity is associated with heightened fear responses, social withdrawal, and difficulties in interpreting social cues, which are hallmark symptoms of anxiety in ASD.

Furthermore, the prefrontal cortex, responsible for higher-order cognitive processes such as planning, decision-making, and emotion regulation, often shows reduced connectivity with other brain regions in individuals with ASD. This reduced connectivity has been linked to difficulties in managing emotions, leading to an increased risk of depression. While this fronto-amygdalar disconnectivity is a well-established model for emotion dysregulation derived from the broader depression literature ([10]), studies in ASD cohorts have similarly found that reduced prefrontal control over the amygdala is associated with greater severity of depressive and anxiety symptoms ([23]). Structural imaging studies have also revealed that the prefrontal cortex may be thinner in individuals with ASD and depression, suggesting that neurodevelopmental alterations in this region may contribute to the persistence and severity of depressive symptoms ([49]).

The hippocampus, another critical region for memory formation and emotional regulation, also shows structural and functional abnormalities in individuals with ASD, particularly those with comorbid anxiety and depression. Reduced hippocampal volume has been observed in individuals with ASD and is associated with difficulties in forming new memories and regulating emotional responses, further exacerbating the challenges faced by individuals with these comorbid conditions ([51]).

It should be noted that functional connectivity studies have provided deeper insights into the neurocircuitry underlying ASD and its comorbidities. Functional connectivity refers to the coordinated activity between different brain regions, which is essential for efficient cognitive and emotional functioning. In individuals with ASD, disruptions in functional connectivity between key brain regions have been frequently reported, contributing to the diverse array of cognitive and behavioral challenges associated with the disorder.

One of the most well-documented findings in ASD research is the altered connectivity between the prefrontal cortex and the amygdala. This disrupted connectivity is thought to underlie the emotion regulation difficulties observed in ASD, particularly in those with comorbid anxiety and depression. For example, individuals with ASD often exhibit decreased functional connectivity between these regions during tasks that require emotional regulation, leading to heightened emotional reactivity and difficulties in controlling negative emotions ([23]). This altered connectivity may also contribute to the reduced ability to process and respond to social and emotional stimuli, which is a core challenge in ASD.

In the case of ADHD, which is commonly comorbid with ASD, structural and functional abnormalities have been observed in the basal ganglia and frontal lobes. Meta-analyses confirm structural and functional alterations in the basal ganglia and frontal lobes in ASD populations, and these abnormalities are thought to contribute to the overlapping attentional and behavioral challenges seen when ASD and ADHD co-occur ([19]). These abnormalities are thought to contribute to the attentional and behavioral challenges, such as impulsivity and hyperactivity, that are characteristic of ADHD. Functional neuroimaging studies have further revealed that individuals with ASD and comorbid ADHD often exhibit hypoactivation in the prefrontal cortex during tasks that require sustained attention and inhibitory control ([70]). This hypoactivation is likely a key factor underlying the executive functioning deficits observed in these individuals, making it difficult for them to focus, plan, and execute tasks effectively.

Adverse childhood experiences (ACEs) are significant stressors encountered during childhood that include exposure to trauma, abuse, neglect, family dysfunction, and social exclusion. The impact of ACEs on neurodevelopment is profound, particularly in children with ASD, who may have pre-existing vulnerabilities in stress regulation and emotional processing. Research consistently demonstrates a strong link between ACEs and an increased risk of developing comorbid mental health disorders such as anxiety, depression, and post-traumatic stress disorder (PTSD) in individuals with ASD ([24]). Children with ASD who experience ACEs are more likely to exhibit severe behavioral and emotional difficulties, including increased aggression, self-injurious behavior, and heightened sensitivity to environmental stressors ([30]). These difficulties often persist into adulthood, leading to chronic mental health challenges and impairing overall quality of life.

One of the primary mechanisms through which ACEs exert their influence is the dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, the body’s central stress response system. Chronic activation of the HPA axis, resulting from sustained exposure to stress, can lead to long-term alterations in cortisol levels. These alterations can negatively impact brain regions critical for emotional regulation, such as the amygdala, hippocampus, and prefrontal cortex ([65]). In individuals with ASD, who may already have atypical neurobiological responses to stress, these changes can significantly increase vulnerability to anxiety and depression.

Additionally, the experience of ACEs can disrupt typical patterns of social and emotional learning, further complicating the development of adaptive coping strategies. Early intervention programs that specifically address the emotional and social needs of children with ASD who have experienced ACEs are crucial. Such programs can provide children with tools to process their experiences, develop resilience, and prevent the long-term mental health consequences often associated with early trauma.

Socioeconomic status (SES) is another critical environmental factor that significantly impacts the mental health outcomes of individuals with ASD. The association between low SES and adverse mental health outcomes is well-documented across various populations, and children with ASD are particularly vulnerable to the compounded effects of poverty, limited access to resources, and social inequalities ([18]).

Families with lower SES often face significant barriers in accessing healthcare, educational resources, and social support services, which are crucial for the early identification and treatment of ASD and its comorbidities. Delays in diagnosis and intervention can exacerbate the severity of both core ASD symptoms and associated mental health disorders, making timely access to services a critical factor in improving long-term outcomes ([4]).

Moreover, the chronic stress associated with financial instability and limited access to resources can have a profound impact on parental mental health. Parents of children with autism frequently experience elevated levels of stress, anxiety, and depression, which can negatively affect their ability to provide consistent care and support ([2]). The bidirectional relationship between parental mental health and child outcomes is well-established, with research indicating that higher levels of parental stress are associated with more severe behavioral and emotional problems in children with ASD ([14]).

The social environment plays a critical role in the mental health of individuals with ASD. Studies have consistently shown that individuals with strong social support networks are less likely to develop anxiety and depression, highlighting the protective effects of social connectedness ([11]). Social support can come from various sources, including family, friends, peers, and community organizations, and can provide emotional, practical, and informational assistance that helps individuals with ASD cope with stress and challenges.

Interventions that promote social inclusion and community engagement are particularly important for improving mental health outcomes in individuals with ASD. Peer mentoring programs, where individuals with ASD are paired with trained peers who provide support and guidance, have been shown to improve social skills, reduce feelings of isolation, and enhance self-esteem ([57]). Similarly, supported employment initiatives that provide job training and workplace accommodations for individuals with ASD can significantly improve their mental health and overall well-being by fostering a sense of purpose and achievement ([5]).

Access to quality healthcare services is essential for the early identification and treatment of comorbid mental health disorders in individuals with autism. Integrated care models that bring together mental health professionals, primary care providers, and autism specialists have been shown to improve the coordination and effectiveness of care for individuals with ASD and comorbid conditions ([37]). These models emphasize the importance of a holistic approach to care that addresses the full range of an individual’s needs, including medical, psychological, social, and educational support. For example, the use of multidisciplinary teams that include psychologists, psychiatrists, speech and language therapists, and occupational therapists allows for a comprehensive assessment of the individual’s needs and the development of personalized intervention plans. These teams can work collaboratively to address both the core symptoms of ASD and the comorbid mental health disorders, ensuring that treatment is tailored to the individual’s unique profile ([54]).

In addition, the integration of mental health services into primary care settings can facilitate early detection of comorbid conditions, reduce barriers to accessing specialized care, and promote continuity of care ([69]). This approach is particularly important for individuals with ASD who may have difficulty navigating complex healthcare systems and who benefit from coordinated care that is easily accessible.

Interventions for comorbid mental health disorders in ASD vary in their level of empirical support. Established interventions with support from randomized controlled trials (RCTs) in ASD populations include adapted Cognitive-Behavioral Therapy (CBT) for anxiety. Manualized programs like the Behavioral Interventions for Anxiety in Children with Autism (BIACA) have demonstrated efficacy in reducing anxiety symptoms ([67]; [61]). Pharmacologically, stimulants (e.g., methylphenidate) have RCT evidence for managing ADHD symptoms in individuals with ASD, though they may be associated with increased irritability, necessitating careful monitoring ([60]). SSRIs for depression and anxiety in ASD show mixed results in controlled trials, and their use requires monitoring for behavioral activation ([64]).

In contrast, emerging and experimental approaches such as virtual reality (VR) therapy and transcranial magnetic stimulation (TMS) are supported by preliminary studies with smaller sample sizes. While VR shows promise for reducing phobias ([38]) and TMS for modulating mood ([48]), they are not yet considered first-line treatments. A practical note for clinicians: Regardless of the intervention, close monitoring for adverse effects, such as increased anxiety, agitation, or changes in sleep patterns, is crucial, as individuals with ASD may exhibit unique sensitivities to both behavioral and pharmacological treatments.

Recent advances in treatment and clinical practice have provided new hope for individuals with autism and comorbid mental health disorders. Pharmacological treatments, such as selective serotonin reuptake inhibitors (SSRIs) and stimulants, have been used to manage symptoms of anxiety, depression, and ADHD in individuals with autism, although their efficacy and safety profiles require careful consideration due to the unique neurobiology of autism ([60]). For instance, while SSRIs are commonly prescribed for anxiety and depression, their effects on individuals with ASD can be variable, and some individuals may experience increased agitation or behavioral problems ([64]).

Behavioral therapies, including cognitive-behavioral therapy (CBT) and mindfulness-based interventions, have shown promise in treating anxiety and depression in individuals with ASD ([67]). These therapies are often adapted to meet the specific needs of individuals with autism, incorporating visual aids, social stories, and other tools to enhance understanding and engagement ([34]). For example, modified CBT programs that focus on identifying and challenging negative thought patterns, developing coping strategies, and practicing relaxation techniques have been shown to reduce anxiety symptoms in children and adolescents with ASD ([61]).

Furthermore, emerging research on neuromodulation techniques, such as transcranial magnetic stimulation (TMS) and neurofeedback, offers potential new avenues for treatment. These approaches aim to modulate brain activity in targeted regions associated with comorbid mental health disorders, providing a non-invasive option for individuals who may not respond to traditional therapies ([13]). For instance, TMS has been used to target the prefrontal cortex in individuals with ASD and comorbid depression, with studies showing reductions in depressive symptoms and improvements in mood regulation ([48]).

In addition to pharmacological and behavioral interventions, recent advances in technology have opened up new possibilities for the treatment of comorbid mental health disorders in individuals with autism. For example, virtual reality (VR) therapy has been explored as a tool for reducing anxiety and improving social skills in individuals with ASD ([38]). VR therapy allows individuals to practice social interactions and coping strategies in a safe, controlled environment, with the potential to generalize these skills to real-world situations.

The development of personalized medicine approaches, which tailor treatments to an individual’s genetic, neurobiological, and environmental profile, also holds promise for improving outcomes for individuals with ASD and comorbid mental health disorders. For example, pharmacogenetic testing, which examines how an individual’s genetic makeup affects their response to medications, could help identify the most effective and least harmful treatments for individuals with autism ([53]). Similarly, advancements in neuroimaging and biomarker research could lead to more accurate diagnosis and monitoring of treatment progress in individuals with ASD and comorbid conditions ([17]).